Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 3, 2010, Pages 507-516

  Park, Yeon Hee ^a   Lee, Soohyeon ^a   Cho, Eun Yoon ^a   Choi, Yoon La ^a   Lee, Jeong Eon ^a   Nam, Seok Jin ^a   Yang, Jung Hyun ^a   Ahn, Jin Seok ^a   Im, Young Hyuck ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

ER status; HER2 overexpressing breast cancer; Metastasis; Relapse pattern

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL TIME; AGE; BONE TUMOR; BREAST TUMOR; CROSS-SECTIONAL STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HOSPITALIZATION; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TIME; TUMOR RECURRENCE; VALIDATION STUDY;

ADULT; AGE FACTORS; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 77954676724     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1190-7     Document Type: Article

References (23)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747-752
2. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423
3. Marchiò C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS (2008) The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216:399-407
4. Prat A, Baselga J (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with coexpression of HER2. Nat Clin Pract Oncol 5:531-542
5. Kun Y, How LC, Hoon TP, Bajic VB, Lam TS, Aqqarwal A, Sze HG, Bok WS, Yin WC, Tan P (2003) Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Hum Mol Genet 12:3245-3258
6. Munzone E, Curigliano G, Rocca A, Bonizzi G, Goldhirsch A, Nolè F (2006) Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 8:1-4
7. Loo LW, Grove DI, Williams EM, Neal CL, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI, Malone KE, Daling JR (2004) Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 64:8541-8549
8. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R (2006) Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66:8266-8273
9. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA (2006) Genes associated with breast cancer metastatic to bone. J Clin Oncol 24:2261-2267
10. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549
11. Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P (2006) The tumor suppressor Smad4 is required for transforming growth factor ß-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66:2202-2209
12. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518-524
13. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108-3114
14. Fogarty MP, Kessler JD, Wechsler-Reya RJ (2005) Morphing into cancer: the role of developmental signaling pathways in brain tumor formation. J Neurobiol 64:458-475
15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschov J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant (HERA) Trial Study Team (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672 (Pubitemid 41464705)
16. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR (2005) Molecular evolution of breast cancer. J Pathol 205:248-254
17. Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117:3155-3163
18. Stemmler HJ, Heinemann V (2008) Central nervous system metastases in HER2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 13:739-750
19. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welsch RS, Maqee B, Wilson G, Howell A, Wardley AM (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639-643
20. Park YH, Park MJ, Ji SH, Yi SH, Lim DH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park KC, Im YH (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100:894-900
21. Osborne CK, Schiv R (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23:1616-1622
22. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663-666
23. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fugua SA, Wong J, Allred DC, Clark GM, Schiv R (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361